What Is the Difference Between Alpha GPC and Choline?
Alpha GPC and Choline are both choline donors, but they deliver choline differently. Alpha GPC is a glycerophosphocholine ester that is about 41% choline by weight and splits into choline and glycerophosphate. Choline supplies choline plus cytidine, which is converted to uridine and feeds phospholipid synthesis. In published research, Alpha GPC has the deeper physical-performance record, while Choline has the deeper neuroprotection, membrane-repair and safety record.
Alpha GPC 400MGView Alpha GPC 400MG
Choline 500MGView Choline 500MG
Chemical Identity of Alpha GPC and Choline
PubChem lists Alpha GPC as choline alfoscerate, CID 657272: [(2R)-2,3-dihydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate, C8H20NO6P, 257.22 g/mol, CAS 28319-77-9. It lists Choline as Choline, CID 13804: [[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] 2-(trimethylazaniumyl)ethyl phosphate, C14H26N4O11P2, 488.32 g/mol, CAS 987-78-0. Neither is a peptide.
Molecular Data
Alpha GPC
| Property | Value |
|---|---|
| CAS# | 28319-77-9 |
| PubChem ID | CID 657272 |
| Molecular Formula | C8H20NO6P |
| Molecular Weight | 257.22 g/mol |
| Exact Mass | 257.1028 Da |
| IUPAC Name | [(2R)-2,3-dihydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate |
| InChIKey | SUHOQUVVVLNYQR-MRVPVSSYSA-N |
| SMILES | C[N+](C)(C)CCOP(=O)([O-])OC[C@@H](CO)O |
| Molecular Class | Glycerophospholipid metabolite (choline ester of sn-glycero-3-phosphate) |
| Stereocenters | 1 defined, 0 undefined |
| Hydrogen bond donors / acceptors | 2 / 6 |
| XLogP3 (computed) | -2.3 |
Values from PubChem CID 657272 (computed by PubChem).
Choline
| Property | Value |
|---|---|
| CAS# | 987-78-0 |
| PubChem ID | CID 13804 |
| Molecular Formula | C14H26N4O11P2 |
| Molecular Weight | 488.32 g/mol |
| Exact Mass | 488.1073 Da |
| IUPAC Name | [[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] 2-(trimethylazaniumyl)ethyl phosphate |
| InChIKey | RZZPDXZPRHQOCG-OJAKKHQRSA-N |
| SMILES | C[N+](C)(C)CCOP(=O)([O-])OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=NC2=O)N)O)O |
| Molecular Class | Nucleotide-activated choline; phosphatidylcholine biosynthesis intermediate |
| Stereocenters | 4 defined, 0 undefined |
| Hydrogen bond donors / acceptors | 4 / 11 |
| XLogP3 (computed) | -4 |
Values from PubChem CID 13804 (computed by PubChem).
Key Figures From the Research
- ~41%: Alpha GPC choline density by weight, reported in the review literature
- MD +1.72: Cognition score improvement, α-GPC + acetylcholinesterase enzyme inhibitor meta-analysis (7 RCTs)
- +46%: 10-year stroke risk hazard, α-GPC users in the 12M+ Korean NHIS cohort
- 44×: Acute peak growth hormone response reported with α-GPC in resistance-exercise research
What Is Alpha GPC?
Alpha GPC (L-alpha-glycerylphosphorylcholine, also called choline alfoscerate) is a glycerophosphocholine ester composed of a glycerol backbone, a phosphate group, and a choline moiety. Its choline content is approximately 41% by weight, one of the highest choline densities among commonly studied choline-donor compounds (Li et al., J Food Sci 2025). Alpha GPC has been reported to cross the blood-brain barrier in preclinical models.
In cells, glycerophosphocholine is also an ordinary metabolite: it is formed when phosphatidylcholine is broken down, and it can be split again into choline and glycerophosphate. Research interest in Alpha GPC centers on choline delivery for acetylcholine synthesis, cognition in aging and dementia models, and physical-performance studies.
What Is Choline?
Choline is a naturally occurring intermediate in the Kennedy pathway of phosphatidylcholine biosynthesis. It hydrolyzes into choline and cytidine, with cytidine subsequently converted to uridine, giving the compound what the neurochemistry literature describes as a dual mechanism: cholinergic signaling via the choline moiety plus phospholipid/membrane and neuronal ATP metabolism relevance via the cytidine/uridine pathway (Adibhatla & Hatcher, Neurochem Res 2005).
Inside cells, Choline is made from phosphocholine and CTP by the enzyme CTP:phosphocholine cytidylyltransferase, the rate-limiting step of phosphatidylcholine synthesis (Adibhatla & Hatcher 2005). Research interest centers on membrane phospholipid repair, ischemic stroke and neuroprotection models, and vascular cognitive impairment.
Choline Content by Weight
Each molecule carries one choline group, so the share of weight that is choline depends on the size of the rest of the molecule. Calculated from PubChem molecular weights, the choline cation (104.17 g/mol) is about 40.5% of Alpha GPC (257.22 g/mol) and about 21.3% of Choline (488.32 g/mol). The Alpha GPC figure matches the approximately 41% reported in the review literature. The remainder of the molecule is the nucleotide portion, which supplies cytidine rather than extra choline.

Mechanism Comparison
Both compounds are characterized as choline donors. The mechanisms diverge in the metabolic fate of the non-choline fraction and the downstream pathways that fraction enters.
Alpha GPC: Direct High-Density Choline Donor
Reported to break down enzymatically into a choline fraction (a direct substrate for acetylcholine synthesis via choline acetyltransferase) and a glycerophosphate fraction examined for its role in phospholipid synthesis. Choline density at approximately 41% by weight (Li 2025). Upregulation of brain-derived neurotrophic factor (BDNF) and modulation of α7 nicotinic acetylcholine receptor signaling (Putri et al., Neuropsychiatr Dis Treat 2026).
Choline: Dual Cholinergic + Phospholipid Pathway
Hydrolyzes into choline (feeding into acetylcholine synthesis, similar to other choline donors) and cytidine, with cytidine converted to uridine. Uridine enters the Kennedy pathway for phosphatidylcholine synthesis and to support plasma membrane resealing and neuronal ATP metabolism research (Adibhatla & Hatcher 2005). Additional, Choline upregulations Sirtuin-1 (SIRT1) in ischemic-stroke models (Hurtado et al., J Neurochem 2013).

Alpha GPC delivers a denser, more direct choline load. Choline research literature more frequently emphasizes plasma membrane resealing and neuronal ATP-metabolic pathways alongside cholinergic effects, because the non-choline fragment (cytidine/uridine) is a substrate for phospholipid biosynthesis.
Visual Comparison of Research-Evidence Depth
The chart below scores each compound on a normalized 0-5 scale across seven research dimensions. Scores reflect the depth of the published record for that specific dimension.

Scoring Methodology and Per-Cell Rationale
| Research dimension | Alpha GPC | Choline |
|---|---|---|
| Neurodegenerative Models | 4: 7 RCTs pooled in meta-analysis; MD +1.72 with an acetylcholinesterase enzyme inhibitor | 4: extensive vascular cognitive decline literature |
| Neuroprotection / cerebrovascular | 3: Mathew scale & MMSE benefit; heterogeneous designs | 5: dominant Choline literature; multi-lab replication |
| Membrane-repair / phospholipid | 2: via glycerophosphate fraction | 5: direct Kennedy pathway substrate |
| Physical performance research | 4: Ziegenfuss 2008 (44× GH), Bellar 2015, 2017 | 1: not a primary focus area |
| Choline density by weight | 5: ~41% choline (one of highest) | 3: lower per-mass choline, dual pathway |
| Long-term safety data | 2: 12M+ cohort reports +46% 10-yr stroke HR | 4: favorable tolerability across multiple RCTs |
| Independent replication depth | 4: replicated across cognition, GH, ischemia | 5: decades of multi-lab replication |
Interpretive note. Higher bars indicate deeper published research evidence in that specific dimension. Alpha GPC leads on choline density and physical-performance research. Choline leads on membrane-repair, neuroprotection, and long-term safety-signal depth. Both are well-represented in cognition/dementia research.
Research Focus Areas
The following domain summary condenses the primary areas in which each compound is most heavily represented in the peer-reviewed literature.
| Research domain | Alpha GPC | Choline |
|---|---|---|
| Neurodegenerative models | Well represented; ASCOMALVA-style RCTs, α-GPC + an acetylcholinesterase enzyme inhibitor meta-analysis (Sagaro 2023) | Well represented, particularly vascular cognitive decline research |
| Neuroprotection / cerebrovascular | Studied in cholinergic and phospholipid-related contexts; improved Mathew-scale outcomes in stroke meta-analysis (Sagaro & Amenta 2023) | Extensively studied in ischemic injury and membrane-repair models; ICTUS/CAISR trials (Gusev & Martynov 2015) |
| Hyper Exertion research | Explored in relation to growth hormone secretion and isometric force production in exercise studies (Ziegenfuss 2008; Bellar 2015) | Not a primary focus area in current literature |
| Neurodegenerative disease models | Studied in Alzheimer’s and vascular dementia research (Cantone 2024) | Studied in Parkinson’s disease and glaucoma research alongside dementia models |
| Long-term observational cohorts | 12-million-person Korean NHIS cohort reports dose-dependent +46% 10-year stroke hazard for α-GPC users (Lee et al., JAMA Netw Open 2021) | Comparatively favorable tolerability profile across long-term studies |
Cognitive and Dementia Research
Alpha GPC: Cognition RCT Meta-Analysis
A systematic review and meta-analysis of 7 RCTs and 1 prospective cohort study reported that α-GPC in combination with an acetylcholinesterase enzyme inhibitor produced a mean difference of +1.72 (95% CI 0.20 to 3.25) on cognition scores versus an acetylcholinesterase enzyme inhibitor alone, with functional-outcome MD +0.79 and behavioral-outcome MD −7.61 (Sagaro, Traini & Amenta, J Alzheimer’s Dis 2023). A 2024 mixed randomized/open-label trial reported ADAS-Cog improved by 18.5% at 24 weeks in the an acetylcholinesterase enzyme inhibitor + α-GPC arm versus 9.4% in the an acetylcholinesterase enzyme inhibitor-only arm (Lee & Kim, Medicine 2024).
An acute, randomized, double-blind, placebo-controlled crossover trial in resistance-trained males tested two single α-GPC amounts (315 mg and 630 mg) against placebo and reported significantly improved Stroop test performance (Kerksick, Nutrients 2024).
Choline: Vascular Cognitive Decline Focus
The Choline literature is comparatively concentrated on vascular cognitive impairment, dementia associated with cerebrovascular disease, and neuroprotection. Reviews of the field describe Choline’s therapeutic actions across multiple stages of the ischemic cascade in preclinical models (Gusev & Martynov, J Exp Pharmacol 2015; Álvarez-Sabín & Román, Brain Sci 2013).
An 8-week randomized single-blind study using transcranial magnetic stimulation reported restoration of intracortical excitability measures in acute ischemic stroke patients receiving Choline sodium salt (Benussi et al., Front Neurol 2022).
Neuroprotection and Cerebrovascular Research
A 2023 systematic review and meta-analysis compared both compounds head-to-head as choline-containing phospholipids in acute stroke research (Sagaro & Amenta, J Clin Med 2023). Reported findings:
- Choline: Did not improve NIHSS < 1 (OR 1.05, 95% CI 0.87-1.27) or mRS < 1 (OR 1.36, 95% CI 0.99-1.87) in the pooled analysis of acute-stroke trials.
- Choline alphoscerate (Alpha GPC): Improved neurological function and functional recovery on the Mathew’s scale and MMSE across pooled stroke trials in the same analysis.
Preclinical mechanistic work on Choline continues to report neuroprotective signaling in ischemic-stroke models, including Sirtuin-1 (SIRT1) upregulation concomitant with neuroprotection (Hurtado et al., J Neurochem 2013) and reductions in GFAP, NF-L, and MBP serum biomarkers (Kuryata et al., Neurophysiology 2021).
Physical Performance Research
Hyper Exertion models is the domain where the two compounds most clearly diverge in published depth. Alpha GPC has been repeatedly investigated in resistance-led research populations; Choline has not been a primary focus in this domain.
- Growth hormone response: An abstract in the resistance-led research literature reported that a single α-GPC administration before a resistance-exercise session raised peak growth hormone approximately 44-fold versus placebo baseline (from 0.19 ± 0.06 to 8.4 ± 2.1 ng/mL) in a resistance-exercise protocol (Ziegenfuss et al., J Int Soc Sports Nutr 2008). A 2024 double-blind crossover trial did not detect a group difference in growth hormone at either amount tested (315 or 630 mg) (Kerksick 2024), differences continue to be investigated in the literature.
- Isometric output: A six-day α-GPC study in 13 college-aged men (double-blind, placebo-controlled crossover design) measured isometric mid-thigh pull peak force and an upper-body isometric test against placebo (Bellar et al., J Int Soc Sports Nutr 2015).
Key Similarities and Differences
Key Similarities
- Both are classified as choline-donor compounds studied for their relevance to acetylcholine synthesis and cholinergic signaling research.
- Both are reported in the literature to cross the blood-brain barrier, making them relevant to central nervous system research.
- Both are studied in cognitive research contexts, particularly in aging and vascular cognitive decline populations.
Key Differences
- Alpha GPC has a higher choline density by weight (~41%) than Choline; Choline contributes choline alongside a cytidine/uridine pathway.
- Choline places comparatively stronger emphasis on neuroprotection, plasma membrane repair, and ischemic injury models via the cytidine/uridine → phosphatidylcholine pathway.
- Long-term cerebrovascular risk signals have been raised more specifically for α-GPC in a 12M+ observational cohort; Choline literature to date reports comparatively fewer such signals.
Comparison Summary
- Highest reported choline density by weight: Alpha GPC (~41%).
- Deepest Plasma membrane-repair / neuroprotection literature: Choline.
- Deepest physical performance and growth hormone research record: Alpha GPC.
- Most-replicated cognition + an acetylcholinesterase enzyme inhibitor combination signal: Alpha GPC (7 RCTs, MD +1.72 pooled).
- Only compound with a large-cohort long-term stroke-risk signal on record: Alpha GPC (Korean NHIS cohort, +46% 10-year hazard).
- Best-characterized dual-pathway mechanism: Choline (choline + cytidine/uridine).
Modern Aminos supplies both materials for laboratory research use only: Alpha GPC 400MG and Choline 500MG. For compound-specific detail, see the individual monographs on Alpha GPC and Choline.
Related Research
References
- Sagaro GG, Traini E, Amenta F. Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis. J Alzheimer’s Dis 2023. PMC10041421
- Lee G, Choi HY, Yang SJ, Kim K, Choi S, Chang J, et al. Association of L-α Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years. JAMA Netw Open 2021. PMC8613599
- Sagaro GG, Amenta F. Choline-Containing Phospholipids in Stroke Treatment: A Systematic Review and Meta-Analysis. J Clin Med 2023. PMC10143951
- Ziegenfuss T, Landis J, Hofheins JE. Acute supplementation with alpha-glycerylphosphorylcholine augments growth hormone response to, and peak force production during, resistance exercise. J Int Soc Sports Nutr 2008. PMC3313098
- Bellar D, LeBlanc NR, Campbell B. The effect of 6 days of alpha glycerylphosphorylcholine on isometric strength. J Int Soc Sports Nutr 2015. PMC4650143
- Marcus L, Soileau J, Judge LW, Bellar D. Evaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance. J Int Soc Sports Nutr 2017. PMC5629791
- Kerksick CM. Acute Alpha-Glycerylphosphorylcholine Supplementation Enhances Cognitive Performance in Healthy Men. Nutrients 2024. PMC11644786
- Lee W, Kim M. Comparative study of choline alfoscerate as a combination therapy with an acetylcholinesterase enzyme inhibitor: A mixed double-blind randomized controlled and open-label observation trial. Medicine 2024. PMC11175912
- Cantone AF, Burgaletto C, Cantarella G, et al. Pharmacological enhancement of cholinergic neurotransmission alleviates neuroinflammation and improves functional outcomes in a triple transgenic mouse model of Alzheimer’s disease. Front Pharmacol 2024. PMC11002120
- Zhao Y, Zwinderman K, Wang Z, et al. The Nutritional Supplement L-Alpha Glycerylphosphorylcholine Promotes Atherosclerosis. IJMS 2021. DOI 10.3390/ijms222413477
- Li J, Zhang J, Wang Y, et al. L-Alpha-Glycerylphosphorylcholine (L-α-GPC): A Comprehensive Review of Its Preparation Techniques and Versatile Biological Effects. J Food Sci 2025. DOI 10.1111/1750-3841.70338
- Putri V, Hapsari R, Amalia R. L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders. Neuropsychiatr Dis Treat 2026. DOI 10.2147/NDT.S579603
- Adibhatla RM, Hatcher JF. Nucleotide-Activated Choline in Stroke and Other CNS Disorders. Neurochem Res 2005. PMC1934404
- Hurtado O, Hernández-Jiménez M, Zarruk JG, et al. Choline increases Sirtuin1 expression concomitant to neuroprotection in experimental stroke. J Neurochem 2013. DOI 10.1111/jnc.12269
- Gusev EI, Martynov MY. Current knowledge on the neuroprotective and neuroregenerative properties of Choline in acute ischemic stroke. J Exp Pharmacol 2015. PMC4863531
- Álvarez-Sabín J, Román GC. The Role of Choline in Neuroprotection and Neurorepair in Ischemic Stroke. Brain Sci 2013. PMC4061873
- Benussi A, Premi E, Gilberti N, et al. Choline Treatment in Acute Ischemic Stroke: A Randomized, Single-Blind TMS Study. Front Neurol 2022. PMC9340348
- Kuryata O, Kushnir Y, Nedzvetsky V, Korsa V, Tykhomyrov A. Serum Levels of Biomarkers Associated with Astrocytosis, Neurodegeneration, and Demyelination: Neurological Benefits of Choline Treatment. Neurophysiology 2021. DOI 10.1007/s11062-021-09907-3
- Kansakar U, Trimarco V, Manzi MV, et al. Choline supplements: An update. Front Endocrinol 2023. PMC10025538
- Roy P, Tomassoni D, Nittari G, Traini E, Amenta F. Effects of choline containing phospholipids on the neurovascular unit: A review. Front Cell Neurosci 2022. PMC9541750
Frequently Asked Questions
What Is the Difference Between Alpha GPC and Choline?
Alpha GPC (L-alpha-glycerylphosphorylcholine) is a glycerophosphocholine ester that breaks down into choline (feeding acetylcholine synthesis) and a glycerophosphate fraction. Choline is a naturally occurring Kennedy-pathway intermediate that hydrolyzes into choline plus cytidine, with cytidine subsequently converted to uridine and studied for its role in phospholipid synthesis and brain energy metabolism (Adibhatla & Hatcher 2005).
Which Has a Higher Choline Content by Weight: Alpha GPC or Choline?
Alpha GPC. The review literature reports Alpha GPC contains approximately 41% choline by weight, one of the highest choline densities among commonly studied choline-donor compounds (Li et al., J Food Sci 2025). Choline contributes choline as part of a larger molecule that also includes cytidine, so its per-mass choline delivery is lower, but its cytidine/uridine fraction feeds a separate phospholipid-synthesis pathway not accessed by Alpha GPC in the same way.
Do Both Compounds Cross the Blood-Brain Barrier?
Yes. Both Alpha GPC and Choline are reported in the peer-reviewed literature to cross the blood-brain barrier, which is why both are studied as centrally-active choline-donor research compounds relevant to acetylcholine synthesis and central nervous system research (Kansakar et al., Front Endocrinol 2023).
What Does the Meta-Analysis Literature Say About Alpha GPC in Cognitive Research?
A 2023 systematic review and meta-analysis of 7 RCTs and 1 prospective cohort study reported that α-GPC combined with an acetylcholinesterase enzyme inhibitor produced a mean difference of +1.72 (95% CI 0.20 to 3.25) on cognition scores versus an acetylcholinesterase enzyme inhibitor alone, with mean differences of +0.79 (functional outcomes) and −7.61 (behavioral outcomes). Patients receiving α-GPC alone had significantly better cognition than those receiving placebo or other medications (MD +3.50, 95% CI 0.36 to 6.63) (Sagaro, Traini & Amenta, J Alzheimer’s Dis 2023).
What Is the Reported Growth Hormone Response to Alpha GPC in Exercise Research?
An abstract in the resistance-exercise research literature reported that a single α-GPC administration before a resistance-exercise session raised peak growth hormone approximately 44-fold versus placebo baseline (from 0.19 ± 0.06 to 8.4 ± 2.1 ng/mL) in a resistance-exercise protocol (Ziegenfuss et al. 2008). A separate 2024 double-blind crossover trial did not detect a group difference in growth hormone at either amount tested (315 or 630 mg) (Kerksick, Nutrients 2024), so dose, timing, and cohort factors continue to be investigated.
Is Choline Effective in Acute Ischemic Stroke Research?
The evidence is mixed. Early trials and preclinical models reported neuroprotection across multiple stages of the ischemic cascade (Gusev & Martynov 2015), but a 2023 pooled meta-analysis found that Choline did not significantly improve NIHSS below 1 (OR 1.05, 95% CI 0.87-1.27) or mRS below 1 (OR 1.36, 95% CI 0.99-1.87) across acute-stroke RCTs (Sagaro & Amenta, J Clin Med 2023). Newer preclinical work continues to report SIRT1-mediated neuroprotection signaling (Hurtado 2013).
What Long-Term Safety Signals Have Been Reported for Alpha GPC?
A 2021 matched cohort study of more than 12 million Korean adults aged 50+ without underlying stroke, Alzheimer’s, or cerebrovascular disease reported that α-GPC use was associated with a dose-dependent +46% higher 10-year stroke hazard versus non-users (Lee et al., JAMA Netw Open 2021). A preclinical mouse study reported that dietary α-GPC promoted atherosclerosis and elevated TMAO-producing gut bacteria (Zhao et al., IJMS 2021). Both findings are observational/preclinical and remain subjects of ongoing research.
Do the Two Compounds Have Overlapping Research Use Cases?
Yes. Both are studied as centrally-acting choline donors relevant to acetylcholine synthesis, and both appear in cognitive research contexts, particularly in aging and vascular cognitive decline populations. Reviews of the choline-supplement literature discuss them side-by-side as cholinergic-pathway research materials (Kansakar et al. 2023).
Which Compound Is More Studied in Athletic Performance Research?
Alpha GPC. The published record on Alpha GPC in athletic and resistance-exercise populations includes work on growth hormone response, isometric force production, countermovement jump velocity and mechanical power, and psychomotor performance (Ziegenfuss 2008; Bellar 2015; Marcus 2017). Choline is not a primary focus in this domain.
What’s the Mechanistic Difference in How Each Contributes to Phospholipid Synthesis?
Alpha GPC contributes via its glycerophosphate fraction after cleaving off choline. Choline enters phospholipid synthesis more directly: cytidine is converted to uridine and then to UTP, which participates in the Kennedy pathway of phosphatidylcholine biosynthesis. This is why the Choline literature more heavily emphasizes membrane-repair and brain energy metabolism endpoints (Adibhatla & Hatcher, Neurochem Res 2005).
Are Alpha GPC and Choline Studied Together in Research?
Yes, a 2023 systematic review and meta-analysis directly compared both compounds as choline-containing phospholipids in acute stroke research (Sagaro & Amenta, J Clin Med 2023). Both compounds also appear side-by-side in general choline-supplement reviews (Kansakar et al. 2023) and in reviews of choline-containing phospholipids in the neurovascular unit (Roy et al., Front Cell Neurosci 2022).
What Research Is Available on Alpha GPC and Parkinson’s Disease?
Alpha GPC has been examined in Alzheimer’s disease and vascular dementia research more than in Parkinson’s. A narrative review notes preclinical Parkinson’s-related work on α-GPC alongside Alzheimer’s and vascular dementia (Putri et al., Neuropsychiatr Dis Treat 2026). Choline has a comparatively larger footprint in Parkinson’s and glaucoma research literature.




